Complete cure and adverse events for terbinafine vs placebo
The review found no eligible studies for this question.
- no estimate extractedStudies not reportedNo studies found
The review found no eligible studies for this question.
Azole leads to higher clinical cure compared with placebo (high certainty).
Azole leads to higher mycological cure compared with placebo (high certainty).
Azole showed no clear difference in adverse events compared with placebo (moderate certainty).
Azole showed no clear difference in recurrence rate compared with placebo (low certainty).
The review found no eligible studies for this question.
Griseofulvin showed no clear difference in clinical cure compared with azole (moderate certainty).
Griseofulvin showed no clear difference in mycological cure compared with azole (moderate certainty).
Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).
It is very uncertain whether griseofulvin changes recurrence rate compared with azole (very low certainty).
Azole probably leads to lower mycological cure compared with terbinafine (moderate certainty).
The review found no eligible studies for this question.
Griseofulvin may leads to lower clinical cure compared with terbinafine (low certainty).
Griseofulvin may leads to lower mycological cure compared with terbinafine (low certainty).
Griseofulvin may leads to higher adverse events compared with terbinafine (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether combination terbinafine plus azole changes clinical cure compared with terbinafine monotherapy (very low certainty).
It is very uncertain whether combination terbinafine plus azole changes mycological cure compared with terbinafine monotherapy (very low certainty).
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).